- Home
- ARQT vs SYNA Comparison
ARQT vs SYNA Comparison
Compare ARQT & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- SYNA
- Stock Information
- Founded
- ARQT 2016
- SYNA 1986
- Country
- ARQT United States
- SYNA United States
- Employees
- ARQT N/A
- SYNA N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- SYNA Computer peripheral equipment
- Sector
- ARQT Health Care
- SYNA Technology
- Exchange
- ARQT Nasdaq
- SYNA Nasdaq
- Market Cap
- ARQT 3.3B
- SYNA 2.7B
- IPO Year
- ARQT 2020
- SYNA 2002
- Fundamental
- Price
- ARQT $28.01
- SYNA $60.40
- Analyst Decision
- ARQT Strong Buy
- SYNA Strong Buy
- Analyst Count
- ARQT 7
- SYNA 7
- Target Price
- ARQT $22.17
- SYNA $89.71
- AVG Volume (30 Days)
- ARQT 3.1M
- SYNA 417.7K
- Earning Date
- ARQT 10-28-2025
- SYNA 11-06-2025
- Dividend Yield
- ARQT N/A
- SYNA N/A
- EPS Growth
- ARQT N/A
- SYNA N/A
- EPS
- ARQT N/A
- SYNA N/A
- Revenue
- ARQT $317,929,000.00
- SYNA $1,109,100,000.00
- Revenue This Year
- ARQT $85.27
- SYNA $11.05
- Revenue Next Year
- ARQT $30.70
- SYNA $11.32
- P/E Ratio
- ARQT N/A
- SYNA N/A
- Revenue Growth
- ARQT 129.21
- SYNA 13.24
- 52 Week Low
- ARQT $9.19
- SYNA $41.80
- 52 Week High
- ARQT $28.96
- SYNA $89.81
- Technical
- Relative Strength Index (RSI)
- ARQT 71.06
- SYNA 32.34
- Support Level
- ARQT $22.26
- SYNA $62.24
- Resistance Level
- ARQT $24.39
- SYNA $69.90
- Average True Range (ATR)
- ARQT 1.46
- SYNA 2.48
- MACD
- ARQT 0.21
- SYNA -1.04
- Stochastic Oscillator
- ARQT 85.67
- SYNA 4.16
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.